NMT Medical (NMTI) Lowers Q2 and FY Revenue Gudiance
NMT Medical, Inc. (NASDAQ: NMTI) sees Q2 revenues approximately $3.2 million and for the full year 2009 of of approximately $14 to $15 million, versus prior guidance $3.8 to $4.3 million, and in the range of $16 to $18 million for full year 2009.
CEO Frank Martin said, "product registration in those target markets has taken longer than expected, which resulted in the revenue shortfall during the second quarter. Despite this delay, we are continuing to increase our commercial market share in those markets and we are making progress in our geographic expansion. We expect to realize top-line benefits from these actions during the second half of this year."
Martin also said they are confident that they have the cash necessary to complete ongoing trials and, assuming receipt of regulatory approvals, commercially launch our products.
CEO Frank Martin said, "product registration in those target markets has taken longer than expected, which resulted in the revenue shortfall during the second quarter. Despite this delay, we are continuing to increase our commercial market share in those markets and we are making progress in our geographic expansion. We expect to realize top-line benefits from these actions during the second half of this year."
Martin also said they are confident that they have the cash necessary to complete ongoing trials and, assuming receipt of regulatory approvals, commercially launch our products.
You May Also Be Interested In
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
- Patriot Coal (PCX) shares halted on breaker, bouncing as co. says entered into $625M financing
Create E-mail Alert Related Categories
Guidance, Hot ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
